Shares of Lineage Cell Therapeutics (NYSEMKT: LCTX) were soaring by 19.4% as of 12:01 p.m. EDT on Tuesday. The big gain came after the company announced positive news from a phase 1/2a study evaluating OpRegen in treating dry age-related macular degeneration (AMD).
Lineage Cell Therapeutics reported it observed restoration of retinal tissue in two additional patients in its study of OpRegen. The company reported its first case of retinal restoration last year. CEO Brian Culley said, “To our knowledge, these three patients represent the only examples of an experimental treatment for dry AMD demonstrating a reduction, rather than attenuating further expansion, of an area of atrophy in humans.”
The news is so encouraging that Lineage filed a Patent Cooperation Treaty (PCT) patent application for the restoration of the anatomy and/or functionality of diseased retinas. This filing enables the company to seek patent protection in multiple countries simultaneously. If Lineage receives approval for its patent application, it would have intellectual property protection at least through May 24, 2041.
Lineage now plans to discuss its detailed findings from the study of OpRegen with external therapeutic experts. The company also will evaluate its pathways for regulatory approval of the allogeneic retinal pigment epithelium (RPE) cell transplant therapy. With three of four patients who received OpRegen so far experiencing retinal tissue restoration, the prospects for this biotech stock appear bright.
10 stocks we like better than Lineage Cell Therapeutics, Inc.
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and Lineage Cell Therapeutics, Inc. wasn’t one of them! That’s right — they think these 10 stocks are even better buys.
*Stock Advisor returns as of May 11, 2021